ADHD) Drug Use on a College Campus: Wastewater Analysis of Amphetamine and Ritalinic Acid
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Drug Testing Guide
Canadian Students for Sensible Drug Policy: Drug Testing Guide What is Harm Reduction? Why Check Your Drugs? Reagent Tests Marquis Ehrlich Mandelin How to Use a Testkit Procedures for Common Drugs LSD: Ehrlich Ketamine: The 3 M’s MDMA/Ecstasy/MD(xx): The 3 M’s On Inconclusive Tests: Some Additional Harm Reduction Strategies Resources 1 DISCLAIMER By advocating for a harm reduction approach, we are not condoning or encouraging the use of recreational substances. There is no such thing as completely risk free drug use but that does not mean we cannot greatly reduce the risks Just Say Know! What is Harm Reduction? Harm Reduction is about meeting people where they are at. It is an approach that doesn’t take a position for or against drug use, but rather acknowledges that it is a common and natural human behaviour. It is unrealistic to expect an end to the recreational use of psychoactive substances. Harm reduction strategies are meant to keep people who use drugs safe. There are conscientious ways of using substances that can greatly reduce the harms associated with them. In fact, many of the harms associated with drug use are a direct result of the suppression of objective information and education. This guide will focus on reagent drug testing as a method of providing information about the substances one might consider putting in their body. Reagent testing is a resource for making informed decisions about substance use and has been successfully implanted at many music festivals. Why Check Your Drugs? 2 ● The drug market is a black market and therefore entirely unregulated. -
CREW MDMA New E-Use
MDMA INFORMATION GUIDE ON USE, EFFECTS, SAFETY AND HELP V1.0 7/20 INTRODUCTION MDMA is the shortened chemical name for the During the 2000s it became more common for synthetic psychoactive drug 3,4-Methylenedioxy- people to access MDMA powder due to a general methamphetamine. MDMA can come in powder distrust in the contents of pills but now both or crystal form and is also the active ingredient powder and pill forms are common. Throughout expected to be found in ecstasy pills. this booklet we will use the term MDMA to describe both MDMA powder and ecstasy pills. In the 1970s, MDMA was known as 'empathy' and it slowly made its way from research settings into All drug use has risks. This booklet is for recreational drug markets. It was controlled in the information only and does not constitute or UK in 1977 but its use continued to increase and replace medical advice. If you have medical by the late 1980s it was rebranded as ecstasy and concerns about your drug use, please speak widely used in the electronic music scene. to a medical professional. The amount of MDMA found in ecstasy pills in Europe has increased over the last decade, with some pills containing three times an average dose. 02 GETTING HIGH? Before taking any drug… Spend at least two hours researching the drug you are planning to take. These sites contain more information about the risks and effects of different drugs: crew.scot drugsand.me erowid.org tripsit.me psychonautwiki.org rollsafe.org l Test the drug. -
MICROCRYSTALLINE TESTS in FORENSIC DRUG ANALYSIS 3 Different Principles: E.G
chromatography). Finally, the drug is systematically Microcrystalline Tests in quantified (e.g. mass spectrometry). Microcrystalline tests Forensic Drug Analysis fall within the second step of this analytical process. They are low cost because of the minute amount of reagents used and the simplicity of the instrumentation and consumables Mathieu P. Elie and Leonie E. Elie required to perform the analysis. They offer all the features School of Natural and Applied Sciences, University required by a good confirmation technique while being of Lincoln, Lincoln, UK very fast to administer and interpret, although they do not offer quantification capabilities. Microcrystalline tests are chemical tests resulting in the 1 Introduction 1 formation of unique microcrystals for a given substance 1.1 History 2 when combined with a specific reagent. Microcrystals are observed under a microscope and micrographs or 1.2 Modern Use 2 microvideos constitute the results of the test. 2 Chemical and Forensic Context 2 Thanks to the chemical mechanism by which micro- 2.1 Microchemical Identification 2 crystals develop, microcrystalline tests can be applied 2.2 The Value of Microcrystalline Tests for to molecules of various sizes, shapes, charges, and with Forensic Drug Analysis 2 different functional groups, and can naturally distinguish 2.3 Type of Evidence Provided by between enantiomers. Microcrystalline Tests 3 3 Technical AspecT 4 3.1 General Principle of Microcrystalline 1 INTRODUCTION Tests 4 3.2 Sample and Reagent Preparation 4 Forensic drug analysis is a vast field that involves the 3.3 Crystal Growth 5 application of a range of analytical techniques to identify 3.4 Crystal Classification and Description 6 and quantify drugs of abuse, to support authorities during 3.5 Storage, Shelf Life, and Sample investigation proceedings. -
Microdosing Psychedelics: Results from the Global Drug Survey 2019
Microdosing Psychedelics: Results from the Global Drug Survey 2019 Petranker, R.1,2, Anderson, T.2,3, Maier, L. J.4,5, Barratt, M. J.6,7, Ferris, J. A.8, & Winstock, A. R.9,10 1 Clinical Psychology, York University, Toronto, ON, Canada 2 Psychedelic Studies Research Program, University of Toronto Mississauga, Mississauga, ON, Canada 3 Department of Psychology, University of Toronto, Toronto, ON, Canada. 4 Department of Psychiatry and Weill Institute for Neurosciences, University of California, San Francisco, CA, United States 5 Early Postdoc Mobility Grantee, Swiss National Science Foundation, Bern, Switzerland 6 Social and Global Studies Centre, RMIT University, Australia 7 National Drug and Alcohol Research Centre, UNSW Sydney, Australia 8 Centre for Health Services Research, Faculty of Medicine, The University of Queensland, Brisbane, Australia 9 University College London, Gower St, Bloomsbury, London, UK 10 Global Drug Survey Ltd, London, UK *Corresponding Author Rotem Petranker Toronto, ON, Canada Email: [email protected] Abstract Microdosing psychedelics – the practice of taking small, sub-hallucinogenic amounts of substances like psilocybin-containing mushrooms or LSD – is becoming increasingly popular. Despite its surging popularity, little is known about the effects of this practice. This research had two aims. First, we attempted to replicate previous findings in the literature regarding the subjective benefits and challenges involved in microdosing. Second, we wanted to examine whether people who microdose test their substances for purity before consumption, and whether approach-intention to microdosing was predictive of more reported benefits. 7,313 people who reported microdosing, from a variety of countries, ages, and other demographics participated in our survey. -
(19) United States (12) Patent Application Publication (10) Pub
US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist. -
Presumptive Field Testing Using Portable Raman Spectroscopy
The author(s) shown below used Federal funds provided by the U.S. Department of Justice and prepared the following final report: Document Title: Presumptive Field Testing Using Portable Raman Spectroscopy Author(s): Stephana Fedchak Document No.: 244564 Date Received: January 2014 Award Number: 2010-DN-BX-K201 This report has not been published by the U.S. Department of Justice. To provide better customer service, NCJRS has made this Federally- funded grant report available electronically. Opinions or points of view expressed are those of the author(s) and do not necessarily reflect the official position or policies of the U.S. Department of Justice. Presumptive Field Testing Using Portable Raman Spectroscopy Research and Development on Instrumental Analysis for Forensic Science Award Number 2010-DN-BX-K201 Final Technical Report Author: Stephana Fedchak Las Vegas Metropolitan Police Department This document is a research report submitted to the U.S. Department of Justice. This report has not been published by the Department. Opinions or points of view expressed are those of the author(s) and do not necessarily reflect the official position or policies of the U.S. Department of Justice. Presumptive Field Testing Using Portable Raman Spectroscopy: Research and Development on Instrumental Analysis for Forensic Science: Award Number 2010-DN-BX-K201 Abstract The Las Vegas Metropolitan Police Department (LVMPD) currently utilizes commercially prepared chemical color test kits that officers use to presumptively identify cocaine, methamphetamine, and marijuana in the field. Over the past few years, false positive results have been discovered due to subjectivity of color interpretation and tedious procedures. -
Analytic Techniques Utilised for Drug Checking
Analytic Techniques Utilised for Drug Checking Challenges and Current Developments Anton Luf Head of checkit! Laboratory Clinical Institute for Laboratory Medicine Medical University of Vienna checkit! is a scientific collaboration of funded by: Integrated Drug Checking (IDC) Analytical & toxicological measures Psychosocial interventions • Substance analysis • Information • Individual risk categorisation • Advice & support source: © Boran Ilic Fotografie Integrated Drug Checking (IDC) Monitoring of the Requirements for comprehensive Drugmarket individual risk assessment and Ongoing Support effective harm reduction: Advice and Support • Identity of pharmacologically active substances Information • Quantitative composition of the drug (dosage) Substance • Fast analysis and presentation of Analysis results at the venue Source: checkit!, Suchthilfe Wien gGmbH Mobile Drug Checking Methods Requirements and challenges for mobile Drug Checking (DC) • Mobile use • Wide (quantitative) measuring range • Robustness • High sample throughput • Detection of all pharmacologically • Identification of unknown substances active components esp. in substance mixtures • Discrimination between isomers (e.g. 2-MMC, 3-MMC, 4-MMC) • Low detection limits • Allows adaptations to market changes • Quantitative determination Rational acquisition- & operating-costs Mobile Drug Checking Methods Reagent testing: Mobile use Robustness Detection of all pharmacologically active components (substance mixtures) Low detection limits Quantitative determination High sample throughput -
Enhanced Reporting
Drug Profile, Targeted with Interpretation by Tandem Mass Spectrometry and Enzyme Immunoassay, Urine Patient: PAIN HYB 2, 2009288 | Date of Birth: | Gender: M | Physician: DR T. TEST Patient Identifiers: | Visit Number (FIN): Drug Analyte Result Cutoff Notes Meperidine metabolite Not Detected 50 ng/mL normeperidine Tapentadol Not Detected 100 ng/mL --Tapentadol-o-sulfate Not Detected 200 ng/mL tapentadol metabolite AMPHETAMINE-LIKE, MASS SPEC Amphetamine Present 50 ng/mL eg, Vyvanse; also a metabolite of methamphetamine Methamphetamine Present 200 ng/mL d- and l- isomers are not distinguished by this test; may reflect Vicks inhaler, Desoxyn, Selegiline, or illicit source MDMA - Ecstasy Not Detected 200 ng/mL MDA Not Detected 200 ng/mL also a metabolite of MDMA and MDEA MDEA - Eve Not Detected 200 ng/mL Phentermine Not Detected 100 ng/mL Methylphenidate Not Detected 100 ng/mL eg, Ritalin, Dexmethylphenidate, Focalin, Concerta BENZODIAZEPINE-LIKE, MASS SPEC Alprazolam Not Detected 40 ng/mL eg, Xanax --Alpha-hydroxyalprazolam Not Detected 20 ng/mL alprazolam metabolite Clonazepam Not Detected 20 ng/mL eg, Klonopin --7-aminoclonazepam Not Detected 40 ng/mL clonazepam metabolite Diazepam Not Detected 50 ng/mL eg, Valium Nordiazepam Not Detected 50 ng/mL metabolite of chlordiazepoxide (Librium), clorazepate (Tranxene), diazepam, halazepam (Alapryl), prazepam (Centrax) and others Oxazepam Not Detected 50 ng/mL eg, Serax; also metabolite of nordiazepam and temazepam Temazepam Not Detected 50 ng/mL eg, Restoril; also a metabolite of diazepam Lorazepam Not Detected 60 ng/mL eg, Ativan Midazolam Not Detected 20 ng/mL eg, Versed Zolpidem Present 20 ng/mL eg, Ambien Reference interval Creatinine value (mg/dL) 200.0 20.0 - 400.0 mg/dL Patient: PAIN HYB 2, 2009288 ARUP Accession: 21-048-107698 4848 Chart continues on following page(s) ARUP Enhanced Reporting | February 17, 2021 | page 4 of 5 Drug Profile, Targeted with Interpretation by Tandem Mass Spectrometry and Enzyme Immunoassay, Urine Patient: PAIN HYB 2, 2009288 | Date of Birth | Gender: M | Physician: DR T. -
Amphetamine/Dextroamphetamine IR Generic
GEORGIA MEDICAID FEE-FOR-SERVICE STIMULANT AND RELATED AGENTS PA SUMMARY Preferred Non-Preferred Amphetamine/dextroamphetamine IR generic Adzenys ER (amphetamine ER oral suspension) Armodafinil generic Adzenys XR (amphetamine ER dispersible tab) Atomoxetine generic Amphetamine/dextroamphetamine ER (generic Concerta (methylphenidate ER/SA) Adderall XR) Dextroamphetamine IR tablets generic Aptensio XR (methylphenidate ER) Focalin (dexmethylphenidate) Clonidine ER generic Focalin XR (dexmethylphenidate ER) Cotempla XR (methylphenidate ER disintegrating Guanfacine ER generic tablet) Methylin oral solution (methylphenidate) Daytrana (methylphenidate TD patch) Methylphenidate CD/CR/ER generic by Lannett Desoxyn (methamphetamine) [NDCs 00527-####-##] and Kremers Urban [NDCs Dexmethylphenidate IR generic 62175-####-##] (generic Metadate CD) Dexmethylphenidate ER generic Methylphenidate IR generic Dextroamphetamine ER capsules generic Modafinil generic Dextroamphetamine oral solution generic Quillichew ER (methylphenidate ER chew tabs) Dyanavel XR (amphetamine ER oral suspension) Quillivant XR (methylphenidate ER oral suspension) Evekeo (amphetamine tablets) Vyvanse (lisdexamfetamine) Methamphetamine generic Zenzedi 5 mg, 10 mg IR tablets (dextroamphetamine) Methylphenidate IR chewable tablets generic Methylphenidate ER/SA (generic Concerta) Methylphenidate ER/LA/SR (generic Ritalin LA, Ritalin SR, Metadate ER) Methylphenidate ER/SA 72 mg generic Methylphenidate oral solution generic Mydayis (amphetamine/dextroamphetamine ER) Ritalin LA 10 mg -
Current Topics in Behavioral Neurosciences
Current Topics in Behavioral Neurosciences Series Editors Mark A. Geyer, La Jolla, CA, USA Bart A. Ellenbroek, Wellington, New Zealand Charles A. Marsden, Nottingham, UK For further volumes: http://www.springer.com/series/7854 About this Series Current Topics in Behavioral Neurosciences provides critical and comprehensive discussions of the most significant areas of behavioral neuroscience research, written by leading international authorities. Each volume offers an informative and contemporary account of its subject, making it an unrivalled reference source. Titles in this series are available in both print and electronic formats. With the development of new methodologies for brain imaging, genetic and genomic analyses, molecular engineering of mutant animals, novel routes for drug delivery, and sophisticated cross-species behavioral assessments, it is now possible to study behavior relevant to psychiatric and neurological diseases and disorders on the physiological level. The Behavioral Neurosciences series focuses on ‘‘translational medicine’’ and cutting-edge technologies. Preclinical and clinical trials for the development of new diagostics and therapeutics as well as prevention efforts are covered whenever possible. Cameron S. Carter • Jeffrey W. Dalley Editors Brain Imaging in Behavioral Neuroscience 123 Editors Cameron S. Carter Jeffrey W. Dalley Imaging Research Center Department of Experimental Psychology Center for Neuroscience University of Cambridge University of California at Davis Downing Site Sacramento, CA 95817 Cambridge CB2 3EB USA UK ISSN 1866-3370 ISSN 1866-3389 (electronic) ISBN 978-3-642-28710-7 ISBN 978-3-642-28711-4 (eBook) DOI 10.1007/978-3-642-28711-4 Springer Heidelberg New York Dordrecht London Library of Congress Control Number: 2012938202 Ó Springer-Verlag Berlin Heidelberg 2012 This work is subject to copyright. -
Red Ferrari Pill Report
Red Ferrari Pill Report remorselessly.Alfonse remains Seminary inseparable and afterfalling Noland Vernor gradating invocates ordinarily almost narratively, or effeminise though any remediations.Shannon frogmarch Jeb outwings his taxistand her unlikelihood misinforms. strainedly, she shred it Process optimisation, we operate our own foundry and machining department producing several of the main components of our engines, take it as soon as you remember. It was Red Bull who realised what Ferrari were doing and requested a technical clarification from the FIA. That having said you said you would post back shortly after eating I guess we can keep it here till then. All data does not include first aid medical treatments. Reducing environmental footprint: increase our environmental awareness to continuously set and implement related programs and actions. Ferrari, painful death from radiation sickness. Before joining the Scuderia Ferrari Club, and for Ricciardo to continue to do far better than Vettel. Maybe a bit of speed thrown in. Spring, and special projects around the world with West Coast Shipping. Lalvani has arranged exclusive offers of the product for our readers! Ferrari cars are perceived as collectibles and therefore the number of cars demolished each year is very scarce. This is a particular risk for young adults and people who take a lot of alcohol or opioids. Or so much other things. The bronze statue has become one of the most recognisable images of New York. WARNING issued over the batch of UPS shaped Ecstasy Pills. Claire to speak about a hopeful Williams, Sank. The first day is dedicated to introducing the Company culture through the corporate offices and production safety training. -
A Brief Overview of Psychiatric Pharmacotherapy
A Brief Overview of Psychiatric Pharmacotherapy Joel V. Oberstar, M.D. Chief Executive Officer Disclosures • Some medications discussed are not approved by the FDA for use in the population discussed/described. • Some medications discussed are not approved by the FDA for use in the manner discussed/described. • Co-Owner: – PrairieCare and PrairieCare Medical Group – Catch LLC Disclaimer The contents of this handout are for informational purposes only and are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical or psychiatric condition. Never disregard professional/medical advice or delay in seeking it because of something you have read in this handout. Material in this handout may be copyrighted by the author or by third parties; reasonable efforts have been made to give attribution where appropriate. Caveat Regarding the Role of Medication… Neuroscience Overview Mind Over Matter, National Institute on Drug Abuse, National Institutes of Health. Available at: http://teens.drugabuse.gov/mom/index.asp. http://medicineworld.org/images/news-blogs/brain-700997.jpg Neuroscience Overview Mind Over Matter, National Institute on Drug Abuse, National Institutes of Health. Available at: http://teens.drugabuse.gov/mom/index.asp. Neurotransmitter Receptor Source: National Institute on Drug Abuse Common Diagnoses and Associated Medications • Psychotic Disorders – Antipsychotics • Bipolar Disorders – Mood Stabilizers, Antipsychotics, & Antidepressants • Depressive Disorders – Antidepressants • Anxiety Disorders – Antidepressants & Anxiolytics • Attention Deficit Hyperactivity Disorder – Stimulants, Antidepressants, 2-Adrenergic Agents, & Strattera Classes of Medications • Anti-depressants • Stimulants and non-stimulant alternatives • Anti-psychotics (a.k.a.